Surgery & procedures
| Aim for complete macroscopic resection when feasible Aim for complete macroscopic resection when feasible. | Curative | Standard | Curated |
| Unilateral salpingo-oophorectomy often required Unilateral salpingo-oophorectomy often required; hysterectomy/contralateral oophorectomy based on age, stage, and fertility goals. | Curative | Standard | Curated |
| Nodal evaluation considered, especially for alveolar RMS given higher… Nodal evaluation considered, especially for alveolar RMS given higher nodal risk. | Curative | Standard | Curated |
| Fertility-sparing approaches only in highly selected early cases with… Fertility-sparing approaches only in highly selected early cases with multidisciplinary input. | Curative | Standard | Curated |
| Plan en-bloc resection to avoid capsular rupture or tumor spill Plan en-bloc resection to avoid capsular rupture or tumor spill; use a specimen bag for extraction to limit peritoneal seeding. | Curative | Standard | Curated |
| Mark close/deep margins with clips to guide adjuvant radiation planning Mark close/deep margins with clips to guide adjuvant radiation planning. | Curative | Standard | Curated |
| If an unplanned (‘whoops’) resection occurred, restage and consider r… If an unplanned (‘whoops’) resection occurred, restage and consider re-excision to achieve R0 before RT. | Curative | Standard | Curated |
| In bulky disease, consider neoadjuvant chemotherapy to downstage befo… In bulky disease, consider neoadjuvant chemotherapy to downstage before definitive surgery. | Curative | Standard | Curated |
| For oligometastatic disease, discuss metastasectomy or ablation (lung… For oligometastatic disease, discuss metastasectomy or ablation (lung/liver) in tumor board after systemic control. | Curative | Standard | Curated |
| Coordinate ureteral stents or bowel resection with peri-chemo timing… Coordinate ureteral stents or bowel resection with peri-chemo timing to minimize infectious complications. | Curative | Standard | Curated |
Radiotherapy
| Consider for positive margins, nodal involvement, or unresectable/loc… Consider for positive margins, nodal involvement, or unresectable/local recurrence. | — | Standard | Curated |
| Pelvic RT planning must balance organ tolerance and prior surgeries Pelvic RT planning must balance organ tolerance and prior surgeries. | — | Standard | Curated |
| SBRT SBRT can be considered for oligometastatic lung/bone disease. | Advanced / metastatic | Standard | Curated |
| Use IMRT/VMAT to spare bowel, bladder, rectum, and ovaries/uterus whe… Use IMRT/VMAT to spare bowel, bladder, rectum, and ovaries/uterus when organ preservation matters. | — | Standard | Curated |
| Post-op RT Post-op RT is guided by margin status (R1/R2) and nodal disease; pre-op RT is an option for downstaging in select cases. | — | Standard | Curated |
| Spine/bone mets: consider SBRT for pain control and local control Spine/bone mets: consider SBRT for pain control and local control; screen for cord compression symptoms. | — | Standard | Curated |
| Time RT around systemic therapy to minimize overlapping toxicities (e Time RT around systemic therapy to minimize overlapping toxicities (e.g., ifosfamide renal, anthracycline cardiac). | — | Standard | Curated |
| Lung mets: SBRT or wedge resection discussed case-by-case after syste… Lung mets: SBRT or wedge resection discussed case-by-case after systemic response. | — | Standard | Curated |
Chemotherapy
| VAC-based regimens (vincristine, actinomycin, cyclophosphamide) stand… VAC-based regimens (vincristine, actinomycin, cyclophosphamide) standard in pediatric/AYA RMS. | — | Standard | Curated |
| Adult options Adult options include doxorubicin/ifosfamide or gemcitabine/docetaxel (extrapolated from soft-tissue sarcoma). | — | Standard | Curated |
| Platinum/taxane regimens Platinum/taxane regimens are not standard for pure RMS unless mixed histology is present. | — | Standard | Curated |
| Clinical trial enrollment strongly encouraged due to rarity Clinical trial enrollment strongly encouraged due to rarity. | — | Standard | Curated |
| Risk-adapted intensity with early response assessment (typically after 2 Risk-adapted intensity with early response assessment (typically after 2–3 cycles); switch or escalate if inadequate response. | — | Standard | Curated |
| Consider VAC/IVA variants or VDC/IE-style intensity in AYA/fit adults… Consider VAC/IVA variants or VDC/IE-style intensity in AYA/fit adults when tolerated—individualize to comorbidity and goals. | — | Standard | Curated |
| Anthracycline cardioprotection (dexrazoxane) and dose-capping strategies Anthracycline cardioprotection (dexrazoxane) and dose-capping strategies may preserve intensity over longer courses. | — | Standard | Curated |
| Ifosfamide protocols: ensure mesna, aggressive hydration, and CNS/ren… Ifosfamide protocols: ensure mesna, aggressive hydration, and CNS/renal monitoring (encephalopathy, proximal tubulopathy). | — | Standard | Curated |
| Maintenance concepts (e.g., low-dose alkylator/vinca) Maintenance concepts (e.g., low-dose alkylator/vinca) are investigational in adults—prefer within trials. | Maintenance | Standard | Curated |
| VAC (vincristine/actinomycin/cyclophosphamide) (pediatric/AYA) Foundation for pediatric RMS; adult tolerance varies. Use growth-factor prophylaxis; early response check at 2–3 cycles to decide on escalation or switch. | — | Standard | Curated |
| Doxorubicin/Ifosfamide variants (adult STS) Common adult sarcoma backbone; monitor cardiac/renal toxicity. Consider dexrazoxane for cardioprotection; strict mesna/hydration and CNS/renal monitoring for ifosfamide. | — | Standard | Curated |
| Gemcitabine/Docetaxel (recurrent/palliative) Soft-tissue sarcoma option; activity varies in RMS. Useful for symptom control and disease stabilization when curative options are limited. | Advanced / metastatic | Standard | Curated |
| VDC/IE (vincristine/doxorubicin/cyclophosphamide ↔ ifosfamide/etoposi… Intensified alternating regimen; consider for bulky/biologically adverse disease to enable resection. Requires G-CSF, cardioprotection strategy, and tight toxicity monitoring. | — | Standard | Curated |
| IVA (ifosfamide/vincristine/actinomycin) (neoadjuvant/anthracycline-a… Option when avoiding anthracyclines (cardiac risk) or as bridge to surgery; ensure mesna/hydration and neuro/renal surveillance. | Neoadjuvant | Standard | Curated |
| VIT (vincristine/irinotecan/temozolomide) (relapsed/chemo-pretreated) Pediatric-relapse–derived; can debulk or stabilize to open local control windows. Watch GI toxicity and myelosuppression. | — | Standard | Curated |
| High-dose Ifosfamide (salvage) STS-standard salvage with occasional RMS responses; neuro/nephrotoxicity vigilance is essential. Consider when aiming to downstage for consolidative RT/surgery. | — | Standard | Curated |
| Doxorubicin/Dacarbazine (± Ifosfamide) (adult STS legacy) Historic backbone with modest RMS activity; consider case-by-case when other regimens contraindicated. Cardio and marrow safety planning required. | — | Standard | Curated |
| Oral maintenance (vinorelbine + low-dose cyclophosphamide) (post-resp… Exploratory disease-control concept after good response; adult RMS data limited—prefer on protocol. | Maintenance | Standard | Curated |
Targeted therapy
| Anti-angiogenic TKIs (e Anti-angiogenic TKIs (e.g., pazopanib) have limited RMS-specific data; reserve mainly for refractory settings or trials. | — | Standard | Curated |
| IGF1R/PI3K/AKT/mTOR: pathway alterations support trial eligibility IGF1R/PI3K/AKT/mTOR: pathway alterations support trial eligibility; single-agent activity historically limited. | — | Standard | Curated |
| Hedgehog/GLI, MEK/ERK: investigational targets Hedgehog/GLI, MEK/ERK: investigational targets; consider baskets. | — | Guideline option | Curated |
| ctDNA/NGS ctDNA/NGS can inform trial matching and detect resistance patterns. | — | Standard | Curated |
| NTRK fusion (rare): TRK inhibitors (tumor-agnostic) NTRK fusion (rare): TRK inhibitors (tumor-agnostic) can be high-yield when present. | — | Standard | Curated |
| TFCP2-fusion subset: ALK overexpression TFCP2-fusion subset: ALK overexpression—consider ALK-focused trials and keratin-positive RMS recognition. | — | Standard | Curated |
| FGFR4 activation/overexpression: trial-focused FGFR4 inhibitors and e… FGFR4 activation/overexpression: trial-focused FGFR4 inhibitors and emerging CAR-T approaches. | — | Guideline option | Curated |
| PAX–FOXO1 epigenetic dependency: BET/BRD4 inhibition trials and trans… PAX–FOXO1 epigenetic dependency: BET/BRD4 inhibition trials and transcriptional-complex disruption strategies. | — | Standard | Curated |
| YAP/TEAD (Hippo dysregulation): early-phase TEAD inhibitor programs f… YAP/TEAD (Hippo dysregulation): early-phase TEAD inhibitor programs for resistance/stemness biology. | — | Standard | Curated |
| p53–MDM2 axis: MDM2 antagonists in development—consider when TP53 wil… p53–MDM2 axis: MDM2 antagonists in development—consider when TP53 wild-type and MDM2-high. | — | Standard | Curated |
| DDR targeting (PARP/ATR) as radiosensitizers/combos in refractory dis… DDR targeting (PARP/ATR) as radiosensitizers/combos in refractory disease—trial contexts only. | — | Standard | Curated |
| Rational combos to blunt feedback (e.g., PI3K/mTOR + MEK) Rational combos to blunt feedback (e.g., PI3K/mTOR + MEK) should be pursued in trials, not empirically off-label. | — | Guideline option | Curated |
Immunotherapy
| MSI-H/dMMR (rare) MSI-H/dMMR (rare): may enable PD-1 blockade under tumor-agnostic approvals. | — | Standard | Curated |
| Checkpoint inhibitors: modest activity overall Checkpoint inhibitors: modest activity overall; combinations under study. | — | Guideline option | Curated |
Established care shown from OncoForge editorial curation · reviewed September 15, 2025 — authoritative citations (NCI PDQ / FDA) are being added.